Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC and BMMC in Type 1 Diabetes
NCT02940418Phase 1Unknown
- Start
- Feb 2017
- Primary completion
- Nov 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of adipose derived mesenchymal stromal cells in type 1 diabetes mellitus (T1D) (2 arms). Primary endpoint: Safety of using allogenic ASC assessed by any adverse events at 6 months. Status: unknown.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02940418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940418.